TGFBR1 and neoplasm: Importantly, Pdx1-Cre × LSL-KrasG12D × Tp53R172H (KPC) mice administered a combination of the TGFBR1 inhibitor Galunisertib and an anti-PD-1 antibody showed improved overall survival, as well as a substantial increase in tumor-infiltrating lymphocytes, granzyme B deposition, and apoptosis in remaining areas of neoplastic disease [148].